<DOC>
	<DOCNO>NCT00388960</DOCNO>
	<brief_summary>The purpose study document activity safety single agent amrubicin , amrubicin combine cisplatin , etoposide combine cisplatin first-line treatment extensive disease small cell lung cancer .</brief_summary>
	<brief_title>Study Amrubicin With Without Cisplatin Versus Etoposide-cisplatin Extensive Stage Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Amrubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Histologically/cytologically proven small cell lung cancer Extensive disease Measurable disease World Health Organization ( WHO ) performance status 02 Age 18 year old Normal baseline cardiac function No prior systemic chemotherapy small cell lung cancer Adequate organ function include bone marrow , kidney , liver No history interstitial lung disease pulmonary fibrosis No history prior malignancy unless patient disease free great 5 year , tumour nonmelanoma skin cancer insitu carcinoma cervix No pregnancy breast feeding ; patient childbearing potential must agree use appropriate method contraception Written inform consent randomization Exclusion criterion : Preexisting peripheral neuropathy ( great Grade 1 , CTCAE version 3.0 ) Uncontrolled severe cardiovascular disease Any psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>small cell lung cancer</keyword>
	<keyword>amrubicin</keyword>
</DOC>